Global Women’s Healthcare Market Size, by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause), By Region (North America, Europe, Asia Pacific, South America, and the Middle East & Africa), Trend Analysis, Market Competition Scenario & Outlook, 2020-2026

Published:
July 2020
Report Code:
BWC20103
Available Format:
PDF PDF Icon
Pages:
173

women’s healthcare market bwc20103

COVID-19

We've been tracking the direct impact of COVID-19 on this market, and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Contact our sales team for more details at

Contact Now

Global Women’s Healthcare Market – Market Outlook & Trends

 

The Global Women’s Healthcare Market appraised at USD 9.6 billion in 2019 is expected to reach USD 23.81 billion by 2026, at a CAGR of 13.2 % during the projection period. The market's growth is mainly driven by factors such as the rising incidence of chronic illnesses among women, government initiatives to curb population, and growing requests for contraceptives to avoid unintentional pregnancies. Moreover, the growing focus on R&D by key players for the development of advanced products is also another major factor contributing to market development.

 

The increasing female population aged over 60, adoption of unhealthy routine, and innovative medicines induce market growth. Furthermore, promising policies implemented by the government to improve women's health and raise awareness are likely to drive market development during the projection period. Women are at advanced risk of illnesses such as menstrual health-related disorders, osteoporosis, osteoarthritis, anemia, depression, and obesity. Hence, growing occurrences of these conditions are likely to increase the market development in the coming years.

 

Global Women’s Healthcare Market – Overview 

 

Women's health is concerned with the ailments and treatment related to her anatomy and reproductive organs. A woman encounters several issues related to menstruation, pregnancy, menopause, and others during her life. Women's health also includes medical situations in which women face problems not directly linked to their biology but due to gender-differentiated admittance to medical cure. Women's health issues have gained increasing recognition in recent decades worldwide. Effective policies and government initiatives have led to a reduction in women's ailments and have allowed them to live healthier lives. However, some significant gender-based health disparities prevail in many countries. Lack of awareness and lower-income levels in many developing countries remain obstacles making health progress for women very difficult.

 

Key Drivers 

 

Increasing prevalence of age-related health disorders in women

 

Chronic ailments and reproductive issues affect women's health mostly. The factors such as physical inactivity, smoking, alcohol use, depression, and no availability of health services adversely affect women's health. Most women aged 15 to 44 suffer from one of the other sexual and reproductive health problems. Hormonal imbalance concerning prolactin, estrogen, and thyroid is growing in women due to stress and other deficiencies, further triggering demand for the medicine to improve health. The hormonal infertility is anticipated to rise rapidly due to unfavorable conditions in advanced countries and will lead to market growth over the projection period. 

 

Rising Focus on Women's Health by Government and Private Organizations 

 

Governments and various private organizations worldwide emphasize women's health and wish to deliver maximum healthcare benefits while designing and implementing health policies and plans. Progressive coverage plans for women are likely to induce the market in advanced countries. For instance, numerous coverage plans in the US provide preventive services for women without any corresponding charges. The preventive services comprise regular anemia screening, folic acid supplements for pregnant women, hepatitis B tests, breast cancer screening, and contraception. Department of Health and Human Services has recognized the Healthy People 2020 program spanning over ten years to improve the fitness of all Americans.

 

Global Women’s Healthcare Market – Segmentation

 

Based on the drug, the market is divided into Mirena, Zometa, Reclast, Prolia, Xgeva, Evista, Nuvaring, Primarin, and Actonel. Prolia is the fastest-growing section of the market. It also registered the highest market share in 2018. The high prevalence of postmenopausal osteoporosis among women is the main factor responsible for this market segment's growth.


The market is divided into contraceptives, menopause, PCOS, hormonal infertility, postmenopausal osteoporosis, endometriosis, and other applications, based on application. In 2018, the postmenopausal osteoporosis section remained the leading market division during the prediction period. Rising occurrence of postmenopausal osteoporosis, more emphasis on providing a real cure for postmenopausal issues, and high risk of osteoporosis fractures maintained this segment's development. Moreover, factors such as old age and obesity further add to the risk of osteoporosis in women. Therefore, his section is also expected to register the maximum CAGR during the prediction period.


Based on the region, Global Women’s Healthcare Market is segmented by key regions— North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

Global Women’s Healthcare Market - Regional Insights 



The global women’s healthcare market is divided into five major areas: North America, Europe, APAC, Latin America, and the Middle East & Africa. In 2018, North America was the main and the fastest-growing area market for women’s healthcare. The significant factors driving market development include the rising incidence of PCOS and postmenopausal osteoporosis, the growing median age of first-time pregnancies, and increased healthcare expenditure in the US and Canada. Also, the high awareness regarding contraceptives among American women and the easy access to modern contraception compared to emerging countries propel the market development in this region.

 

Competitive Landscape

 

The prominent in women's healthcare are Eli Lilly and Company, Novartis AG; Pfizer Inc., Merck & Co., Inc.; Novo Nordisk A/S; Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, Johnson & Johnson Services Inc., GlaxoSmithKline plc, Bayer AG, Theramex, Agile Therapeutics, Blairex Laboratories Inc., Bristol-Myers Squibb Company, Ferring B.V., Abbott, Enteris BioPharma, Evestra, Inc, Gedeon Richter, HRA Pharma, JDS Therapeutics, LLC, Neurocrine Biosciences Inc., Noven Pharmaceuticals, Inc., Radius Health, Inc., TherapeuticsMD Inc., Bausch Health, Vertical Pharmaceuticals LLC, Veru Inc., BD and AbbVie Inc. and others.

 

Recent Development:

 

In February 2018, CVC VI announced that it had formed a new company known as Theramex that will provide products and therapeutics to women for contraception, fertility, menopause, and osteoporosis. The company will be located in London, England. Its products will be available at the company’s disposal after the acquisition of Teva Pharmaceutical Industries Ltd.’s women's health offerings.


Scope of the Report

 

Attribute

Details

Years Considered

Historical data – 2016-2019

Base Year – 2019

Forecast – 2020 – 2026

Facts Covered

Revenue in USD Billion

Market Coverage

U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Japan, South Korea, China, India, South Korea UAE, South Africa, Saudi Arabia.

Product/Service Segmentation

By Drug, By Application and By Region

Key Players

Eli Lilly and Company, Novartis AG; Pfizer Inc., Merck & Co., Inc.; Novo Nordisk A/S; Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, Johnson & Johnson Services Inc., GlaxoSmithKline plc, Bayer AG, Theramex, Agile Therapeutics, Blairex Laboratories Inc., Bristol-Myers Squibb Company, Ferring B.V., Abbott, Enteris BioPharma, Evestra, Inc, Gedeon Richter, HRA Pharma, JDS Therapeutics, LLC, Neurocrine Biosciences Inc., Noven Pharmaceuticals, Inc., Radius Health, Inc., TherapeuticsMD Inc., Bausch Health, Vertical Pharmaceuticals LLC, Veru Inc., BD and AbbVie Inc.

By Drug


Ø  EVISTA

Ø  XGEVA

Ø  Prolia

Ø  Mirena

Ø  Zometa

Ø  Reclast/Aclasta

Ø  Minastrin 24 Fe

Ø  NuvaRing

Ø  FORTEO

Ø  Premarin

Ø  ACTONEL

Ø  ORTHO TRI-CY LO (28)


By Application


Ø  Hormonal Infertility

Ø  Postmenopausal Osteoporosis

Ø  Endometriosis

Ø  Contraceptives

Ø  Menopause

Ø  Polycystic Ovary Syndrome

Ø  Other Applications   


By Region


Ø  North America

Ø  Europe 

Ø  Asia Pacific

Ø  Latin America

Ø  Middle East & Africa

 

The objective of the Study:

 

Ø  To analyze and project the Global Women’s Healthcare Market size in terms of value.

Ø  To examine the region-wise segmentation of the Global Women’s Healthcare Market and assess the market size in terms of value for each region viz., North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their leading countries. 

Ø  To outline, segregate, and estimate the Global Women’s Healthcare Market based on different classifications, i.e., By Drug, By Application and By Region.

Ø  To scrutinize category-wise competitive developments in the Global Women’s Healthcare Market By Drug, By Application and By Region.

Ø  To interpret the current market dynamics by analyzing growth drivers, restraints, opportunities, and challenges and their impact. 

Ø  To provide a detailed competitive landscape, including major players, strategic profiles, and market shares.

 

Business Questions Answered by the Report

 

Ø  How will the market drivers, restraints, and opportunities affect the market dynamics?

Ø  What will be the market size in terms of value and volume and market statistics with a detailed classification?

Ø  Which segment dominates the market or region, and which one will be the fastest-growing, and why?

Ø  Who are the key players in the market, and what is their share?

Ø  What is the strategy adopted by key players, and how does it affect the existing and new players?

 

Customization Scope for the Client

 

Client satisfaction is our first and last priority, and that is why BlueWeave Consulting offers customization as per client’s specific needs. The following customization options are available for the report:

Ø  Additional Company Information

Ø  Detail Analysis of five additional companies

Ø  Additional country analysis

Ø  Detailed segment analysis

 

 

WHY CHOOSE US

  • 24/7 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Coustom Research Service

    Ask the Analyst to customize an exclusive study to serve your research needs.

  • Quality & Accuracy

    offers best quality reports based on various authentic and accurate data findings.

  • Data Visualization

    As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization

  • Information security

    We never share your personal and confidential information. Your personal information is safe and secure with us.